[{"id":"14b28ae8-831d-4306-9aa4-5c102afbfa3f","acronym":"CARPALL","url":"https://clinicaltrials.gov/study/NCT02443831","created_at":"2021-01-18T11:42:34.871Z","updated_at":"2024-07-02T16:35:00.037Z","phase":"Phase 1","brief_title":"CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies","source_id_and_acronym":"NCT02443831 - CARPALL","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • KMT2A • IGH • CD22 • TCF3","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["ABL1 • BCR • KMT2A • IGH • CD22 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2036","study_completion_date":" 12/31/2036","last_update_posted":"2024-05-30"}]